Furthermore, it is not to be excluded that 68Ga-PSMA-HBED-CC PET imaging may also play a role in treatment response monitoring and selection of those patients suffering from breast carcinoma that may benefit from non-PSMA targeting antiangiogenic treatment strategies either given as monotherapy or in combination with chemotherapy, e.g., bevacizumab, aflibercept, integrin targeting antibodies, sunitinib, sorafenib, gamma-secretase inhibitors, angiopoietin inhibitors, and mTOR inhibitors [27]. This evidence concerns the gene MTOR and breast carcinoma.